Cancer screening in China: a steep road from evidence to implementation

作者：Changfa Xia, Partha Basu, Barnett S. Kramer, Li He, Chunfeng Qu, Xue Qin Yu, Karen Canfell, You‐Lin Qiao, Bruce K. Armstrong, Wanqing Chen · 发表于：The Lancet Public Health · 年份：2023 · DOI：10.1016/s2468-2667(23)00186-x · 被引用次数：148 · 研究领域：Global Cancer Incidence and Screening、Colorectal Cancer Screening and Detection、Cervical Cancer and HPV Research

Cancer screening has the potential to decrease mortality from several common cancer types. The first cancer screening programme in China was initiated in 1958 and the Cancer High Incidence Fields established in the 1970s have provided an extensive source of information for national cancer screening programmes. From 2012 onwards, four ongoing national cancer screening programmes have targeted eight cancer types: cervical, breast, colorectal, lung, oesophageal, stomach, liver, and nasopharyngeal cancers. By synthesising evidence from pilot screening programmes and population-based studies for various screening tests, China has developed a series of cancer screening guidelines. Nevertheless, challenges remain for the implementation of a fully successful population-based programme. The aim of this Review is to highlight the key milestones and the current status of cancer screening in China, describe what has been achieved to date, and identify the barriers in transitioning from evidence to implementation. We also make a set of implementation recommendations on the basis of the Chinese experience, which might be useful in the establishment of cancer screening programmes in other countries.